BIOINVENT: Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma https://t.co/BT6laSKjYO
419 followers
2,454 followers
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma #lymphoma #lymsm https://t.co/UkAdjampWG
925 followers
New article: Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma https://t.co/sh41rrkKLI #MCL #lymsm #hematology https://t.co/Qd4XTKJcqp
2,454 followers
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma #lymphoma #lymsm https://t.co/FKWI1NzM6C